ArticleJournal of translational medicine2018
Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products.
Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Current challenges and future directions of ATMPs in regenerative medicine.Regenerative therapy · 2025Review
- Extracellular vesicles and their mimetics: clinical application prospects in medical aesthetics.Burns & trauma · 2025Article
- Successful transport across continents of GMP-manufactured and cryopreserved culture-expanded human fetal liver-derived mesenchymal stem cells for use in a clinical trial.Regenerative therapy · 2024Article
- Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use.Immunologic research · 2023Article
- Reconstitution and post-thaw storage of cryopreserved human mesenchymal stromal cells: Pitfalls and optimizations for clinically compatible formulants.Regenerative therapy · 2023Article
- Engineering exosomes and biomaterial-assisted exosomes as therapeutic carriers for bone regeneration.Stem cell research & therapy · 2023Review
- Illustrative Potency Assay Examples from Approved Therapies.Advances in experimental medicine and biology · 2023Article
- Preconditioning and Engineering Strategies for Improving the Efficacy of Mesenchymal Stem Cell-Derived Exosomes in Cell-Free Therapy.Stem cells international · 2022Review
- Current GMP standards for the production of vaccines and antibodies: An overview.Frontiers in public health · 2022Review
- Clinically relevant preservation conditions for mesenchymal stem/stromal cells derived from perinatal and adult tissue sources.Journal of cellular and molecular medicine · 2021Article
- Construction of transplantable artificial vascular tissue based on adipose tissue-derived mesenchymal stromal cells by a cell coating and cryopreservation technique.Scientific reports · 2021Article
- Formulation Considerations for Autologous T Cell Drug Products.Pharmaceutics · 2021Review
- Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience.Frontiers in cardiovascular medicine · 2021Article
- Advances in translational orthopaedic research with species-specific multipotent mesenchymal stromal cells derived from the umbilical cord.Histology and histopathology · 2021Review
- Use of Multipotent Mesenchymal Stromal Cells, Fibrin, and Scaffolds in the Production of Clinical Grade Bone Tissue Engineering Products.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Evaluation of a cell-based osteogenic formulation compliant with good manufacturing practice for use in tissue engineering.Molecular biology reports · 2020Article
- Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application.Stem cell research & therapy · 2019Article
- Principal Criteria for Evaluating the Quality, Safety and Efficacy of hMSC-Based Products in Clinical Practice: Current Approaches and Challenges.Pharmaceutics · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSuccessful delivery of cell-based therapeutics into patients is compromised by their short shelf-life upon release from production facilities due to the living nature of the active component that rapidly loses viability, and therefore its properties. In this context, the use of appropriate additives may contribute to the stabilisation of the cellular component within specifications for a longer time until administration.
resultsIn the present study, we evaluated the effect of different formulations on the stability of viability, identity, and potency of clinical grade multipotent mesenchymal stromal cells in suspension, both electrolyte solution and protein content were found to impact on their shelf-life. Particularly cryopreservation of cells in a Plasmalyte 148 supplemented with 2% (w/v) AlbIX (a yeast-derived recombinant albumin) and 10% (v/v) dimethyl sulfoxide, and final formulation post-thawing in Plasmalyte 148 supplemented with 2% (w/v) AlbIX enabling prolonged stability from 24 h up to 72 h in optimal conditions. Further investigation on the mechanisms of action involved revealed a delay of apoptosis progression into late stage when AlbIX was present.
conclusionsThe use of optimal formulations for each cell type of interest is crucial to extend the shelf life of cell-based pharmaceuticals and contribute to solve logistical challenges. We demonstrated that the use of Plasmalyte 148 supplemented with 2% (w/v) AlbIX resulted in superior stability of multipotent mesenchymal stromal cells without affecting their identity and multipotency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.